Featured Publications
Direct targeting of amplified gene loci for proapoptotic anticancer therapy
Kaushik Tiwari M, Colon-Rios DA, Tumu HCR, Liu Y, Quijano E, Krysztofiak A, Chan C, Song E, Braddock DT, Suh HW, Saltzman WM, Rogers FA. Direct targeting of amplified gene loci for proapoptotic anticancer therapy. Nature Biotechnology 2021, 40: 325-334. PMID: 34711990, PMCID: PMC8930417, DOI: 10.1038/s41587-021-01057-5.Peer-Reviewed Original ResearchConceptsDNA double-strand breaksTriplex-forming oligonucleotidesDNA damage responseDouble-strand breaksDrug resistanceGene amplificationP53-independent apoptosisHER2-positive breastOvarian cancer modelHuman tumor xenograftsInduction of apoptosisGenomic lociNumber of drugsCellular functionsDamage responseGene locusProtein productsHER2-positive cancer cellsDriver genesClinical efficacyCombat drug resistanceDNA damageHER2 amplificationTherapeutic strategiesTumor xenografts
2015
TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
Mosrati M, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck A, Bratthäll C, Strandéus M, Stenmark-Askmalm M, Söderkvist P. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015, 6: 16663-16673. PMID: 26143636, PMCID: PMC4599297, DOI: 10.18632/oncotarget.4389.Peer-Reviewed Original ResearchConceptsTERT promoter mutationsShorter overall survivalOverall survivalPromoter mutationsC228TInterleukin-6 expressionPrimary glioblastoma patientsTypes of tumorsReverse transcriptase activityPrognostic factorsShorter survivalIL-6GBM patientsTERT promoter statusGlioblastoma patientsHomozygous carriersC alleleTumours leadsC250TPrimary glioblastomaPromoter statusTERT promoterMinor alleleGlioblastomaTranscriptase activity